stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Shares outstanding
Jazz Pharmaceuticals PLC's shares outstanding at the end of fiscal 2025 was $61.0M, down 7.61% from $66.0M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $64.7M. Over the past ten years it has ranged from $56.5M (fiscal 2020) to $72.1M (fiscal 2023); the current reading is higher than 36% of that period. Jazz Pharmaceuticals PLC ranks 237th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $61.0M | (7.61%) |
| FY2024 | $66.0M | (8.41%) |
| FY2023 | $72.1M | 15.23% |
| FY2022 | $62.5M | 4.77% |
| FY2021 | $59.7M | 5.62% |
| FY2020 | $56.5M | (1.79%) |
| FY2019 | $57.6M | (6.00%) |
| FY2018 | $61.2M | (0.16%) |
| FY2017 | $61.3M | (0.89%) |
| FY2016 | $61.9M | (1.85%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $64.7M | (6.77%) |
| Jun 2026 | $69.4M | 4.99% |
| Mar 2026 | $66.1M | 8.39% |
| Dec 2025 | $61.0M | (1.00%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SMMT Summit Therapeutics PLC compare | $778.2M |
| EXEL Exelixis, Inc. compare | $255.8M |
| BBIO BridgeBio Pharma, Inc. compare | $196.0M |
| BMRN BioMarin Pharmaceutical Inc. compare | $193.6M |
| TECH Bio-Techne Corp compare | $157.0M |
| HALO Halozyme Therapeutics, Inc. compare | $122.6M |
| KYMR Kymera Therapeutics, Inc. compare | $100.1M |
| ASND Ascendis Pharma A/S compare | $68.3M |
| JAZZ Jazz Pharmaceuticals PLC | $64.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement